Tirzepatide cuts risk of diabetes by 94% in adults with prediabetes and obesity or overweight, drugmaker says

A recent three-year study of a medication called tirzepatide has shown promising results for adults with prediabetes and obesity or overweight. The medication, also known as Mounjaro for diabetes and Zepbound for weight loss, significantly lowered the risk of progression to diabetes compared to a placebo. Participants who received a 15mg dose of tirzepatide also experienced a considerable decrease in body weight. However, during a follow-up period, weight regain and an increase in the progression to type 2 diabetes were observed in individuals who had stopped using the medication. The most common side effects reported were related to the gastrointestinal system and were generally mild to moderate in severity. Prediabetes affects a significant number of adults in the US, and lifestyle changes, such as weight loss, have been considered crucial in managing the condition. Tirzepatide works by mimicking hormones that regulate the release of insulin, promote feelings of fullness, and reduce appetite. It is part of a new class of drugs that have gained popularity for diabetes and weight loss. The medication was recently approved for individuals with obesity or those characterized as overweight with weight-related health conditions. Further details of the study will be published in a peer-reviewed journal and presented at a conference.